Recently, the U.S. Food and Drug Administration issued a news release warning the public of a voluntary nationwide recall of one lot of 1% Lidocaine HCL Injection. Hospira, Inc., the product manufacturer as well as the world’s largest provider of injectable drugs, has issued this recall due to the presence oxidized stainless steel found in the drug particulates.
According to the FDA, the specific product recalled is: 1% Lidocaine HCI Injection, USP, 10 mg/mL, 20 mL Multiple-dose Fliptop Vial, NDC 0409-4276-01, Lot 25-090-DK (the lot number may be followed by 01 or 02). These injections were distributed from March 2013 through June 2013.
As stated on the FDA’s website, if injected, consequences can range from “local inflammation, phlebitis, and/or low-level allergic response through mechanical disruption of tissue or immune response to the particulate. Capillaries, which may be as small as the size of a red blood cell, may become occluded. Chronically, following sequestration, some granuloma formation may occur in the lungs.”
The manufacturer released a statement to its customers outlining these potential risks associated with this error, such as strong radiation exposure, and Health Officials are urging medical facilities and physicians who have the affected lot to immediately discontinue use.
To date, Hospira has not received reports of any adverse events associated with this recalled drug lot. If a loved one suffered injury because of a contaminated 1% Lidocaine HCL Injection, contact Lopez McHugh for a free consultation.
